Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets, CFDs, OTC options or any of our other products work and whether you can afford to take the high risk of losing your money.

68% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.

5 Top Stories

New AI Chip; Biotech Breakthrough; Moon Mission Announced

Every day, we handpick the 5 Top Stories stock market investors need to know. In 5 minutes, you’ll learn the stocks, CEOs, and money managers moving markets.

Will New AI Chip Corner the Market?

Artificial intelligence (AI) semiconductor start-up Sapeon, which is backed by SK Telecom [SKM] and SK Hynix [000660:KS], has launched Sapeon X330, a new chip for data centres, which it said “represents roughly twice the computational performance and 1.3 times better power efficiency” relative to competitors’ products. Elsewhere, Microsoft [MSFT] has unveiled its first homegrown AI chip, the Maia 100.

UK Approves Biotech Breakthrough

ARK Invest has long touted CRISPR gene editing as “biotech’s breakthrough of the century”. On Thursday, the UK became the first country to approve a therapy based on it. The Medicines and Healthcare products Regulatory Agency announced on Thursday that it had approved Casgevy, a sickle cell disease and beta thalassaemia treatment based on CRISPR.

Eli Lilly to Build €2bn Plant in Germany

Pharma giant Eli Lilly [LLY] is to open a new €2bn plant in Germany. According to Reuters, the firm, which has seen soaring demand for its diabetes/weight-loss drug Mounjaro, is to formally announce the plans on Friday. Meanwhile, German regulator BfArM is weighing a ban on exports of Novo Nordisk’s [NVO] Ozempic, as EU health systems struggle with shortages.

Space Start-up Undeterred

“We may not have landed on the moon the first time, but the experience and data we gained are vital,” the CEO of Japan’s ispace [9348:T] told reporters on Thursday, announcing the space start-up’s second attempt to land a rover on the lunar surface. Its first attempt failed in April this year; the follow-up is scheduled for the winter of 2024. The lander will launch on a SpaceX Falcon 9 rocket, Bloomberg reported.

Spotify Expands Use of AI

Sweden’s Spotify [SPOT] has been using AI for more than a decade to tailor musical recommendations. Now it is expanding its partnership with Alphabet’s [GOOGL] Google Cloud, and will use the latter’s AI-powered large language models to identify a user’s listening patterns and then make bespoke suggestions of podcasts and audiobooks.

Disclaimer Past performance is not a reliable indicator of future results.

CMC Markets is an execution-only service provider. The material (whether or not it states any opinions) is for general information purposes only, and does not take into account your personal circumstances or objectives. Nothing in this material is (or should be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by CMC Markets or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person.

The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although we are not specifically prevented from dealing before providing this material, we do not seek to take advantage of the material prior to its dissemination.

CMC Markets does not endorse or offer opinion on the trading strategies used by the author. Their trading strategies do not guarantee any return and CMC Markets shall not be held responsible for any loss that you may incur, either directly or indirectly, arising from any investment based on any information contained herein.

*Tax treatment depends on individual circumstances and can change or may differ in a jurisdiction other than the UK.

Continue reading for FREE

Latest articles